Solos buys Lifeline cancer detection line:
This article was originally published in Clinica
Endoscopic instrumentation and medical imaging solutions developer Solos Endoscopy is acquiring Lifeline Biotechnologies' line of early cancer detection products, which include the MastaScope, First Warning system and OvaScope, for $4m in an all-stock transaction. Boston, Massachusetts-based Solos will also pay Lifeline, of Reno, Nevada, royalties on sales exceeding $4m. Lifeline's MastaScope, designed for the early detection of breast cancer, is available internationally, while the company's First Warning system - also used for breast cancer diagnosis - and the OvaScope - designed to detect ovarian cancer - are still under development.
You may also be interested in...
A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.
Aker BioMarine seeks supplement firms to use its EPA/DHA innovation bound by lysophosphatidylcholine to enable the fatty acids to pass through the blood-brain and blood-retinal barriers and boost of eye and brain health benefits. It will submit an NDI notificaion in the US during 2022.
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.